What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Oral PALI-2108 administered once daily for 14 days. Sentinel subjects titrate from 5 mg to 20 mg. Subsequent patients receive a target dose between 10-30 mg based on SRC review, following protocol-specified titration schedules. Dose reductions are permitted for safety. All doses are taken in the fed state. PALI-2108 is an oral, gut-activated PDE4 inhibitor prodrug designed to release its active…”In the company’s words, NCT07428096 on ClinicalTrials.gov
- Tested for
- Ulcerative Colitis (UC), Severe Ulcerative Colitis, Moderate Ulcerative Colitis, Fibrostenotic Crohn's Disease
- Main trialPhase 2
- “The ASCENTRA-UC study is a phase 2 study testing PALI-2108 in patients with moderate to severe ulcerative colitis. Doses of drug will be compared against a placebo to see how well it works, how safe it is, and how the body responds to it.”In the company’s words, NCT07845487 on ClinicalTrials.gov
Other drugs for Ulcerative Colitis (UC)
- TofacitinibPfizer · Phase 3
- UpadacitinibAbbVie · Phase 3
- RisankizumabAbbVie · Phase 3
- UstekinumabJohnson & Johnson (Janssen) · Phase 3
- IcotrokinraJohnson & Johnson (Janssen) · Phase 3
- ObefazimodAbivax S.A. · Phase 3
Coming up1
- Oct 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Oct 2027 | A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis | |
| Phase 1Active, not recruiting | 30 Jan 2026 | A Study of PALI-2108 in Healthy Volunteers, Patients With Ulcerative Colitis, and Patients With Fibrostenosing Crohn's Disease | |
| Phase 1Completed | 7 Jul 2025 | Phase 1 Study Evaluating PALI-2108 in Healthy Volunteers and Ulcerative Colitis Patients. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026